ReviewBlood advances2019
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Review in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.Journal of hematology & oncology · 2026Trial
- Implementing evidence-based restrictive neonatal intensive care unit platelet transfusion guidelines.Journal of perinatology : official journal of the California Perinatal Association · 2024Review
- Role of Serum Interleukin-10 and Interleukin-27 Levels in the Prognosis of Immune Thrombocytopenia in Iraqi Children.Reports of biochemistry & molecular biology · 2024Article
- Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China.Research and practice in thrombosis and haemostasis · 2023Article
- Advances in management of pediatric chronic immune thrombocytopenia: a narrative review.Journal of Yeungnam medical science · 2023Article
- Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.Frontiers in cardiovascular medicine · 2023Review
- Regulatory T-lymphocyte subsets in children with chronic immune thrombocytopenia after high-dose of dexamethasone.Pediatric research · 2022Article
- Therapeutic peptides: current applications and future directions.Signal transduction and targeted therapy · 2022Review
- Immune thrombocytopenic purpura secondary to SARS-CoV-2 infection in a child with acute lymphoblastic leukaemia: a case report and review of literature.BMJ case reports · 2021Article
- Review
- Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia.Yeungnam University journal of medicine · 2021Article
- Review
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug design, development and therapy · 2021Review
- Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment.Haematologica · 2020Article
- Immune Thrombocytopenia in Children: Consensus and Controversies.Indian journal of pediatrics · 2020Review
- The child with immune thrombocytopenia: to treat or not to treat, is that still the question?Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since successful cloning of thrombopoietin (TPO) in 1994, significant advances have been made in the development of recombinant TPO receptor agonists. The US Food and Drug Administration (FDA) has approved 2 agents for use in patients with immune thrombocytopenia (ITP): eltrombopag and romiplostim. Romiplostim is a once-weekly subcutaneous injection that has been shown to increase the platelet count, lessen bleeding, and reduce concurrent medication use in adults with ITP. In December 2018, the US FDA approved romiplostim for use in pediatric patients ≥1 year of age with ITP of >6 months' duration and insufficient response to corticosteroids, immunoglobulins, or splenectomy, based on similarly favorable clinical trial data. In addition, romiplostim is well tolerated, making it an attractive option for the treatment of children. Expansion of off-label romiplostim use is being reported in children for ITP <6 months, neonatal thrombocytopenia, hereditary thrombocytopenias, and chemotherapy- and bone marrow transplant-associated thrombocytopenia. We review here the development of romiplostim with a focus on pediatric use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.